Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 10:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Eye Disorders Clear all
Active, not recruiting No phase listed Observational

A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

NCT06161584
View directory record Official record
Conditions
Geographic Atrophy
Interventions
Pegcetacoplan
Drug
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
60 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
34
States / cities
Bakersfield, California • Beverly Hills, California • Fullerton, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 7, 2026, 10:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Adult Providing Access to the Visual Environment (PAVE) - Glaucoma Pilot

NCT00338208
View directory record Official record
Conditions
Glaucoma
Interventions
Training in the Use of Low Vision Devices
Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
21 Years and older
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 19, 2015 · Synced Sep 7, 2026, 10:22 PM EDT
Completed Phase 1 Interventional

Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma

NCT00003993
View directory record Official record
Conditions
Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
aldesleukin, bryostatin 1
Biological · Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Sep 7, 2026, 10:22 PM EDT
Terminated Not applicable Interventional Results available

OCT-guided LALAK for KCN

NCT01901614
View directory record Official record
Conditions
Corneal Opacity, Keratoconus
Interventions
LALAK, IEK, Retrobulbar Block or General Anesthesia, optical coherence tomography (OCT), Topical Anesthesia, femtosecond laser
Procedure · Drug · Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 100 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Sep 7, 2026, 10:22 PM EDT
Completed Phase 2 Interventional Results available

Study of VVN001 Ophthalmic Solution in Dry Eye Disease

NCT04556838
View directory record Official record
Conditions
Dry Eye
Interventions
VVN001 Ophthalmic Solution 1%, VVN001 Ophthalmic Solution 5%, Vehicle
Drug
Lead sponsor
VivaVision Biotech, Inc
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Sep 7, 2026, 10:22 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension

NCT00945958
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
SPARC0913
Drug
Lead sponsor
Sun Pharma Advanced Research Company Limited
Industry
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Sep 7, 2026, 10:22 PM EDT
Terminated Phase 4 Interventional

Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease

NCT01738243
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Hyaluronic Acid Gel injection, Saline injection
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2021 · Synced Sep 7, 2026, 10:22 PM EDT
Completed Phase 2 Interventional Results available

Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma

NCT01258998
View directory record Official record
Conditions
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, B-cell Adult Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Hairy Cell Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, T-cell Adult Acute Lymphoblastic Leukemia, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Waldenström Macroglobulinemia
Interventions
Akt inhibitor MK2206, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Sep 7, 2026, 10:22 PM EDT
Completed Phase 1 Interventional

In Vivo Dosimetry During Prostate Cancer Radiotherapy

NCT01307852
View directory record Official record
Conditions
Prostate Disease
Interventions
Plastic Scintillation Detectors
Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2016 · Synced Sep 7, 2026, 10:22 PM EDT
Completed No phase listed Observational Results available

Physician's Evaluation of Cyclosporine Ophthalmic Emulsion 0.05%

NCT00827255
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Cyclosporine Ophthalmic Emulsion 0.05%
Drug
Lead sponsor
Allergan
Industry
Eligibility
16 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Sep 7, 2026, 10:22 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Evaluation of Efficacy of Ophthalmic Solution in Induced Allergic Conjunctivitis

NCT00244543
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
R89674 (generic name not yet established)
Drug
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
10 Years and older
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
1
States / cities
North Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 26, 2011 · Synced Sep 7, 2026, 10:22 PM EDT
Completed Not applicable Interventional Results available

SENSIMED Triggerfish Safety and Tolerability

NCT01319617
View directory record Official record
Conditions
Glaucoma
Interventions
SENSIMED Triggerfish
Device
Lead sponsor
Sensimed AG
Industry
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2013 · Synced Sep 7, 2026, 10:22 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Instrument for Glaucoma Early Detection and Monitoring

NCT00578110
View directory record Official record
Conditions
Glaucoma
Interventions
Glaucoma Diagnosis, Name: Neucodia
Device
Lead sponsor
Synabridge Corporation
Industry
Eligibility
40 Years to 75 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
5
States / cities
Birmingham, Alabama • New Haven, Connecticut • Raritan, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2010 · Synced Sep 7, 2026, 10:22 PM EDT
Not listed Phase 1Phase 2 Interventional

Single Ascending Dose Study in Participants With LCA10

NCT03872479
View directory record Official record
Conditions
Leber Congenital Amaurosis 10, Inherited Retinal Dystrophies, Eye Diseases, Hereditary, Retinal Disease, Retinal Degeneration, Vision Disorders, Eye Disorders Congenital
Interventions
EDIT-101
Drug
Lead sponsor
Editas Medicine, Inc.
Industry
Eligibility
3 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
5
States / cities
Miami, Florida • Boston, Massachusetts • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2022 · Synced Sep 7, 2026, 10:22 PM EDT
Completed Not applicable Interventional

Auditory Neural Function in Implanted Patients With Usher Syndrome

NCT04906135
View directory record Official record
Conditions
Usher Syndrome, Cochlear Implantation
Interventions
Experimental manipulation of stimulation parameters
Other
Lead sponsor
Ohio State University
Other
Eligibility
1 Year to 85 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
4
States / cities
Boston, Massachusetts • Columbus, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Sep 7, 2026, 10:22 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma

NCT07209410
View directory record Official record
Conditions
Glaucoma
Interventions
Brimonidine Tartrate Ophthalmic 0.025%
Drug
Lead sponsor
Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Sep 7, 2026, 10:22 PM EDT
Completed Not applicable Interventional

Intervention Trial in Early Age-related Macular Degeneration

NCT01694680
View directory record Official record
Conditions
Age-related Macular Degeneration (AMD)
Interventions
Lutein-enriched-egg beverage (NWT-02), Placebo
Dietary Supplement
Lead sponsor
Newtricious R&D BV
Industry
Eligibility
50 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 20, 2016 · Synced Sep 7, 2026, 10:22 PM EDT
Completed Phase 4 Interventional

Study of the Intraocular Pressure (IOP)-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% in Patients With Glaucoma or Ocular Hypertension

NCT00300079
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Interventions
brinzolamide 1.0%
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Sep 7, 2026, 10:22 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Maestro Agreement and Precision Study II

NCT02376868
View directory record Official record
Conditions
Normal Healthy Subjects With No Known Ocular Diseases, Glaucomatous Eyes, Eyes With Retinal Diseases
Interventions
3D OCT-1 Maestro, iVue
Device
Lead sponsor
Topcon Medical Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Pomona, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Sep 7, 2026, 10:22 PM EDT
Completed Not applicable Interventional Results available

Visual Function and Patient Satisfaction After Bilateral Implantation of AcrySof Natural ReSTOR (Model SN60D3) or AcrySof Natural Monofocal (Model SN60AT)

NCT00759668
View directory record Official record
Conditions
Cataract
Interventions
Acrysof Natural ReSTOR SN60D3, Acrysof Natural Monofocal SN60AT
Device
Lead sponsor
Alcon Research
Industry
Eligibility
50 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jan 25, 2011 · Synced Sep 7, 2026, 10:22 PM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate Safety and Efficacy of rhNGF Eye Drops Solution Versus Vehicle in Patients With Glaucoma

NCT02855450
View directory record Official record
Conditions
Glaucoma
Interventions
rhNGF, Vehicle
Drug
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Sep 7, 2026, 10:22 PM EDT
Terminated Phase 2 Interventional Results available

EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

NCT04437368
View directory record Official record
Conditions
Dry Age-related Macular Degeneration
Interventions
GT005
Drug
Lead sponsor
Gyroscope Therapeutics Limited
Industry
Eligibility
55 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
32
States / cities
Phoenix, Arizona • Huntington Beach, California • Palo Alto, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 7, 2026, 10:22 PM EDT
Completed Not applicable Interventional Results available

Identification of TT Cases by Community Treatment Assistants: An Assessment

NCT01783743
View directory record Official record
Conditions
Trichiasis
Interventions
TT Training Program and TT Screening Card
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
15 Years and older
Enrollment
27,473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 20, 2018 · Synced Sep 7, 2026, 10:22 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Effects of Different Add Powers on the Comfort and Productivity of Computer Users With Fixed or Free Head Movement

NCT00317525
View directory record Official record
Conditions
Refractive Errors, Asthenopia
Interventions
Spectacle Lenses
Device
Lead sponsor
American Optometric Association
Other
Eligibility
40 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 10, 2006 · Synced Sep 7, 2026, 10:22 PM EDT